Diffuse mesothelioma
microRNA-497-5p-based screening identifies a novel synthetic lethal-type interaction via PKMYT1 and WEE1 in pleural mesothelioma
Molecular Therapy, Nucleic Acids 2025 June 17 [Link] Nathanael Pruett, Sierra Wilferd, Anand Singh, Agnes Y Choi, Shivani Dixit, Vivek Singh, Charlize Nguyen, Olivia Lin, David S Schrump, Christopher L Plaisier, Chuong D Hoang Abstract Diffuse pleural mesothelioma (DPM) is an incurable surface neoplasm governed by tumor suppressor losses with limited therapeutic options. Despite the…
Read MoreA giant peritoneal mesothelioma extending to the pelvic floor: A case report and review of the literature
Journal of Cancer Research and Therapeutics 2025 April 1 [Link] Mathew Thomas, Harikrishnan Nandakumar, Parth Sampat, Stephen Graziano Abstract Malignant peritoneal mesothelioma (MPM) is a rare malignancy originating from the peritoneal serosa and is the second most common site of mesothelioma after the pleura. Localized disease presents as a focal circumscribed mass, whereas diffuse disease…
Read MoreEnhanced Detection of Recurrent Diffuse Malignant Peritoneal Mesothelioma Using 68 Ga-FAPI PET/CT Compared to 18 F-FDG PET/CT: A Case Report
World Journal of Nuclear Medicine 2025 March 12 [Link] Marwah Abdulrahman, Ula Al-Rasheed, Ali Dabous, Akram Al-Ibraheem Abstract Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive subtype of epithelioid mesothelioma that arises from the lining of the abdominal cavity. While the applications of traditional fluorine-18 fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography…
Read MoreFollow-up after first-Line nivOlumab plus ipilimumab in patients with diffuse pleuRal mesotheliomA: a real-world Dutch cohort study-FLORA
ESMO Open 2025 February [Link] L H Douma, M M Hofman, F Zwierenga, T M T Zondervan, A I G Buma, H Schouwink, D W Dumoulin, J A Burgers, I Smesseim, J G J V Aerts, C J de Gooijer Abstract Background: Diffuse pleural mesothelioma (dPM) is an aggressive malignancy, primarily treated with palliative systemic…
Read MoreCombining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1-Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study
JTO Clinical and Research Reports 2024 October 24 [Link] Prashasti Agrawal, Michael Offin, Victoria Lai, Michelle S Ginsberg, Prasad S Adusumilli, Valerie W Rusch, Jennifer L Sauter, Teresa Ho, Phillip Wong, Marjorie G Zauderer Abstract Introduction: WT1 often presents on the surface of diffuse pleural mesotheliomas (DPMs) and is an ideal therapeutic target. Galinpepimut-S (GPS),…
Read MoreMajor response of a peritoneal mesothelioma to nivolumab and ipilimumab: a case report, molecular analysis and review of literature
Frontiers in Oncology 2024 July 18 [Link] Marie-Florence Reveneau, Julien Masliah-Planchon, Manuel Fernandez, Abdenour Ouikene, Bernard Dron, Innocenti Dadamessi, Charles Dayen, Lisa Golmard, Bruno Chauffert Abstract Malignant peritoneal mesothelioma (MPM) is a rare tumor associated with a poor prognosis and a lack of consensus regarding treatment strategies. While the Checkmate 743 trial demonstrated the superiority…
Read MorePharmacological inhibition of CDK4/6 impairs diffuse pleural mesothelioma 3D spheroid growth and reduces viability of cisplatin-resistant cells
Frontiers in Oncology 2024 July 1 [Link] Aurora Costa, Iris Maria Forte, Francesca Pentimalli, Carmelina Antonella Iannuzzi, Luigi Alfano, Francesca Capone, Rosa Camerlingo, Alessandra Calabrese, Claudia von Arx, Reyes Benot Dominguez, Massimiliano Quintiliani, Michelino De Laurentiis, Andrea Morrione, Antonio Giordano Abstract Introduction: Diffuse pleural mesothelioma (DPM) of the pleura is a highly aggressive and treatment-resistant…
Read MoreComparative efficacy of immune checkpoint inhibitors versus chemotherapy alone in diffuse pleural mesothelioma
Thoracic Cancer 2024 June 5 [Link] Xuemei Zhang, Lele Chang, Qian Ma, Qian Zhang, Wansu Xu, Qingwei Li Abstract Background: This study aimed to investigate the effects of immune checkpoint inhibitors (ICIs) versus chemotherapy on the prognosis of real-world diffuse pleural mesothelioma patients in China. Methods: Clinical data of 90 patients with diffuse pleural mesothelioma…
Read MoreDiffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
Clinical Cancer Research 2024 April 7 [Link] Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi Abstract Purpose: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA…
Read MoreMolecular and Immunohistochemical Testing in Mesothelioma and Other Mesothelial Lesions
Archives of Pathology and Laboratory Medicine 2024 January 8 [Link] Yin P Hung, Lucian R Chirieac Abstract Context.—: Molecular testing has increasingly been utilized in the evaluation of mesothelioma. Diffuse mesothelioma comprises multiple distinct genetic subgroups. While most diffuse mesotheliomas lack oncogenic kinase mutations and instead harbor alterations involving tumor suppressors and chromatin regulators, a…
Read More